Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1

Current Topics in Medicinal Chemistry

Volumn 4, Issue 9, 2004, Pages 921-944

  Balzarini, Jan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(4,7 DICHLORO 2 BENZOXAZOLYLMETHYL)AMINO] 5 ETHYL 6 METHYL 2(1H) PYRIDONE; ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMINO ACID; AMPRENAVIR; ATEVIRDINE MESYLATE; CAPRAVIRINE; CELL ENZYME; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; ETRAVIRINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; LOVIRIDE; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TIVIRAPINE; TROVIRDINE; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG COST; DRUG DESIGN; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME METABOLISM; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DYSFUNCTION; NONHUMAN; REVIEW; STEVENS JOHNSON SYNDROME; STRUCTURE ANALYSIS; VIRUS INHIBITION; VIRUS MUTANT; VIRUS STRAIN; ANTIBIOTIC RESISTANCE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; VIROLOGY;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MOLECULAR STRUCTURE; REVERSE TRANSCRIPTASE INHIBITORS; SUBSTRATE SPECIFICITY;

EID: 2942524068     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043388420     Document Type: Review

References (224)

1. Baba, M., Tanaka, H., De Clercq, E., Pauwels, R., Balzarini, J., Schols, D., Nakashima, H., Perno, C-F., Walker, R.T. and Miyasaka, T. Highly specific inhibition of human immunodefi-ciency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem. Biophys. Res. Commun. 1989, 165, 1375-1381.
2. Miyasaka, T., Tanaka, H., Baba, M., Hayakawa, H., Walker, R.T., Balzarini, J. and De Clercq, E. A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio) thymine. J. Med. Chem. 1989, 32, 2507-2509.
3. Pauwels, R., Andries, K., Desmyter, J., Schols, D., Kukla, M.J., Breslin, H.J., Raeymaeckers, A., Van Gelder, J., Woestenborghs, R., Heykants, J., Schellekens, K., Janssen, M.A.C., De Clercq, E. and Janssen, P.A.J. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 1990, 343, 470-474.
4. De Clercq, E. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Il Farmaco 1999, 54, 26-45.
5. De Clercq, E. New development in anti-HIV chemotherapy. Biochim. Biophys. Acta 2002, 1587, 258-275.
6. Campani, G., Ramunno, A., Maga, G., Nacci, V., Fattorusso, C., Catalanotti, B., Morelli, E. and Novellino, E. Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors; past, present and future perspectives. Curr. Pharm. Design 2002, 8, 6615-657.
7. Tanaka, H., Takahima, H., Ubasawa, M., Sekiya, K., Inouye, N., Baba, M., Shigeta, S., Walker, R.T., De Clercq, E. and Miyasaka, T. Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents. J. Med. Chem. 1995, 38, 2860-2865.
8. Baba, M.M., Shigeta, S., Yuasa, S., Takashima, H., Sekiya, K., Ubasawa, M., Tanaka, H., Miyasaka, T., Walker, R.T. and De Clercq, E. Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrob. Agents Chemother. 1994, 38, 688-692.
9. Pauwels, R., Andries, K., Debyser, Z., Kukla, M.-J., Schols, D., Breslin, H.J., Woestenborghs, R., Desmyter, J., Janssen, M.A.C., De Clercq, E. and Janssen, P.A.J.New tetrahydroimidazo[4,5-1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2′,3′-dideoxynucleoside analogs. Antimicrob. Agents Chemother. 1994, 38, 2863-2870.
10. Kukla, M.J., Breslin, H.J., Diamond, C.J., Grous, P.P., Ho, C.Y., Miranda, M., Rodgers, J.D., Sherrill, R.G., De Clercq, E., Pauwels, R., Andries, K., Moens, L.J., Janssen, M.A.C. and Janssen, P.A.J Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo [4,5,1-jk][1,4]benzodiazepin-2(1H)-one (TIBO) derivatives. 2. J. Med. Chem. 1991, 34, 3187-3197.
11. Kukla M.J., Breslin, H.J., Pauwels, R., Fedde, C.L., Miranda, M., Scott, M.K., Sherrill, R.G., Raeymaekers, A., Van Gelder, A., Andries, K., Janssen, M.A.C., De Clercq, E. and Janssen, P.A.J. Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin- 2(1H)-one (TIBO) derivatives. J. Med. Chem. 1991, 34, 746-751
12. Pauwels, R., Andries, K., Debyzer, Z., Kukla, M.J., Schols, D., Breslin, H.J., Woestenborghs, R., Desmyter, J., Janssen, M.A.C., De Clercq, E. and Janssen, P.A.J. New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2′,3′-dideoxynucleoside analogs. Antimicrob. Agents Chemother. 1994, 38, 2863-2870.
13. Merluzzi, V.J., Hargrave, K.D., Labadia, M., Grozinger, K., Skoog, M., Wu, J.C., Shin, C.-K., Eckner, K., Hattox, S., Adams, J., Rosenthal, A.S., Faanes, R., Eckner, R.J., Koup, R.A. and Sullivan, J.L. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990, 250, 1411-1413.
14. Hargrave, K.D., Proudfoot, J.R., Grozinger, K.G., Cullen, E., Kapadia, S.R., Patel, U.R., Fuchs, V.U., Maudlin, S.C., Vitous, J., Behnke, M.L., Klunder, J.M., Pal, K., Skiles, J.W., McNeil, D.W., Rose, J.M., Chow, G.C., Skoog, M.T., Wu, J.C., Schmidt, G., Engel, W.W., Eberlein, W.G. and Saboe, T.D. Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones. J. Med. Chem. 1991, 34, 2231-2241
15. Goldman, M.E., Nunberg, J.H., O'Brien, J.A., Quintero, J.C., Schleif, W.A., Freund, K.F., Gaul, S.L., Saari, W.S., J.S. W.S., Hoffman, J.M., Anderson, P.S., Hupe, D.J., Emini, E.A. and Stern, A.M. Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc. Natl. Acad. Sci. USA 1991, 88, 6863-6867.
16. Romero, D.L., Busso, M., Tan, C.-K., Reusser, F., Palmer, J.R., Poppe, S.M., Aristoff P.A., Downey, K.M., So, A.G., Resnick, L., and Tarpley, W.G. Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. USA 1991, 88, 8806-8810.
17. Dueweke, T.J., Poppe, S.M., Romero, D.L., Swaney, S.M., So, A.G., Downey, K.M., Althaus, I.W., Reusser, F., Busso, M., Resnick, L., Mayers, D.L., Lane, J., Aristoff, P.A., Thomas, R.C., and Tarpley, W.G. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother. 1993, 37, 1127-1131.
18. Pérez-Pérez, M.-J., San-Félix, A., Camarasa, M.J., Balzarini, J. and De Clercq, E. Synthesis of [1-[2′,5′-bis-O-(t-butyldimethylsilyl)-(β-D-xylo- and β-D-ribofuranosyl)thymine]-3′-spiro-5″-[4″ -amino-1″, 2″-oxathiole-2″,2″-dioxide]] (TSAO). A novel type of specific anti-HIV agents. Tetrahedron Letters 1992, 33, 3029-3032.
19. Camarasa, M.-J., Pérez-Pérez, M.J., San-Félix, A., Balzarini, J. and De Clercq, E. 3′-Spironucleosides (TSAO derivatives), a new class of specific human immunodeficiency virus type 1 inhibitors. Synthesis and antiviral activity of 3′-spiro-5″-[4″-amino-1″,2″ -oxathiole-2″,2″-dioxide]pyrimidine nucleosides. J. Med. Chem. 1992, 35, 2721-2727.
20. Balzarini, J., Pérez-Pérez, M.-J., San-Félix, A., Schols, D., Perno, C.-F., Vandamme, A.-M., Camarasa, M.-J. and De Clercq, E. 2′,5′-Bis-O -(tert-butyldimethylsilyl)- 3′-spiro- 5″-(4″-amino-1″,2″-oxathiole-2″,2″ -dioxide)pyrimidine (TSAO) nucleoside analogues: highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proc. Natl. Acad. Sci. USA 1992, 89, 4392-4396
21. Pauwels, R., Andries, K., Debyser, Z., P. Van Daele, D. Schols, P. Stoffels, K. De Vreese, R. Woestenborghs, A.-M. Vandamme, C.G.M. Janssen, J. Anné, G. Cauwenbergh, J. Desmyter, J. Heykants, M.A.C. Janssen, E. De Clercq, and P.A.J. Janssen. Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of α-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. USA 1993, 90, 1711-1715.
22. Ahgren, C., Backro, K., Bell, F.W., Cantrell, A.S., Clemens, M., Colacino, J.M., Deeter, J.B., Engelhardt, J.A., Hogberg, M., Jaskunas, S.R., Johansson, N.G., Jordan, C.L., Kasher, J.S., Kinnick, M.D., Lind, P., Lopez, C., Morin J.M. Jr., Muesing, M.A., Noreen, R., Öberg, B., Paget, C.J., Palkowitz, J.A., Parrish, C.A., Pranc, P., Rippy, M.K., Rydergard, C., Sahlberg, C., Swanson, S., Ternasky, R.J., Unge, T., Vasileff, R.T., Vrang, L., West, S.J., Zhang, H. and Zhou, X.X. The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 1995, 39, 1329-1335.
23. Bell, F.W., Cantrell, A.S., Högberg, M., Jaskunas, S.R., Johansson, N.G., Jordan, C.L., Kinnick, M.D., Lind, L., Morin J.M. Jr., Noréen, R., Öberg, B., Palkowitz, J.A., Parrish, C.A., Pranc, P., Sahlberg, C., Ternansky, R.J., Vasileff, R.T., Vrang, L., West, S.J., Zhang, H. and Zhou, X.-X. Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs. J. Med. Chem. 1995, 38, 4929-4936.
24. Zhang, H., Vrang, L., Backbro, K., Lind, P., Sahlberg, C., Unge, T., and Öberg, B. Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127. Antiviral Res. 1995, 28, 331-342.
25. Högberg, M., Sahlberg, C., Engelhardt, P., Noréen, R., Kangasmetsä, J., Johansson, N.G., Öberg, B., Vrang, L., Zhang, H., Sahlberg, B.-L., Unge, T., Lövgren, S., Fridborg, K. and Bä ckbro, K. Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues. J. Med. Chem. 1999, 42, 4150-4160.
26. Sahlberg, C., Noréen, R., Engelhardt, P., Högberg, M., Nangasmetsä, J., Vrang, L. and Zhang, H. Synthesis and anti-HIV activities of urea-PETT analogs belonging to a new class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett. 1998, 8, 1511-1516.
27. Balzarini, J., Pelemans, H., Aquaro, S., Perno, C.-F., Witvrouw, M., Schols, D., De Clercq, E. and Karlsson, A. Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus typ 1 (HIV-1) replication. Mol. Pharmacol. 1996, 50, 394-401.
28. Balzarini, J., Jonckheere, H., Harrison, W.A., Dao, D.C., Anné, J., De Clercq, E. and Karlsson, A. Oxathiin carboxanilide derivatives: a class of non-nucleoside HIV-1-specific reverse transcriptase inhibitors (NNRTIs) that are active against mutant HIV-1 strains resistant to other NNRTIs. Antiviral Chem. Chemother. 1995, 6, 169-178.
29. Buckheit, R.W. Jr., Kinjerski, T.L., Fliakas-Boltz, V., Russell, J.D., Stup, T.L., Pallansch, L.A., Brouwer, W.G., Dao, D.C., Harrison, W.A., Schultz, R.J., Bader, J.P. and Yang, S.S. Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide. Antimicrob. Agents Chemother. 1995, 39, 2718-2727.
30. Buckheit, R.W. Jr., Snow, M.J., Fliakas-Boltz, V., Kinjerski, T.L., Russell, J.D., Pallansch, L.A., Brouwer, W.G. and Yang, S.S. Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates. Antimicrob. Agents Chemother. 1997, 41, 831-837.
31. Kleim, J.-P., Bender, R., Billhardt, U.-M., Meichsner, C., Riess, G., Rösner, M., Winkler, I. and Paessens, A. Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication. Antimicrob. Agents Chemother. 1993, 37, 1659-1664.
32. Kleim, J.-P., Bender, R., Kirsch, R., Meichsner, C., Paessens, A., Rösner, M., Rübsamen-Waigmann, H., Kaiser, R., Wichers, M., Schneweis, K.E., Winkler, I. and Riess, G. Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother. 1995, 39, 2253-2257.
33. Balzarini, J., De Clercq, E., Carbonez, A., Burt, V. and Kleim, J.-P. Long-term exposure of combinations of the novel quinoxaline GW420867X with lamivudine, abacavir and a variety of non-nucleoside reverse transcriptase inhibitors to HIV-1-infected cell cultures AIDS Res. Hum. Retrovir 2000, in press.
34. Artico, M., Massa, S., Mai, A., Marongiu, M.E., Piras, G., Tramontano, E. and La Colla,P. 3,4-Dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs): a new class of specific inhibitors of human immunodeficiency virus type 1. Antiviral Chem. Chemother. 1993, 4, 361-368.
35. Massa, S., Mai, A., Artico, M., Sbardella, G., Tramontano, E., Loi, A.G., Scano, P. and La Colla, P. Synthesis and antiviral activity of new 3,4-dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs), specific inhibitors of human immunodeficiency virus type 1. Antiviral Chem. Chemother. 1995, 6, 1-8.
36. Mai A, Artico, M., Sbardella, G., Massa, S., Loi, A.G., Tramontano, E., Scano, P. and La Colla, P. Synthesis and anti-HIV-1 activity of thio analogues of dihydroalkoxybenzyloxopyrimidines. J Med Chem. 1995, 38, 3258-3263
37. Sudbeck E.A, Mao, C., Vig, R., Venkatachalam, T.K., Tuel-Ahlgren, L. and Uckun, F.M. Structure-based design of novel dihydroalkoxybenzyloxopyrimidine derivatives as potent non-nucleoside inhibitors of the human immunodeficiency virus reverse transcriptase. Antimicrob. Agents Chemother. 1998, 42, 3225-3233.
38. Tucker, T.J., Lyle, T.A., Wiscount, C.M., Britcher, S.F., Young, S.D., Sanders, W.M., Lumma, W.C., Goldman, M.E., O'Brien, J.A., Ball, R.G., Homnick, C.F., Schleif, W.A., Emini, E.A., Huff, J.R. and Anderson, P.S. Synthesis of a series of 4-(arylethynyl)-6-chloro-4-cyclopropyl-3,4-dihydroquinazolin-2(1H)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. J. Med. Chem. 1994, 37, 2437-2444.
39. Young, S.D., Britcher, S.F., Tran, L.O., Payne, L.S., Lumma, W.C., Lyle, T.A., Huff, J.R., Anderson, P.S., Olsen, D.B., Carroll, S.S., Pettibone, D.J., O'Brien, J.A., Ball, R.G., Balani, S.K., Lin, J.H., Chen, I.-W., Schleif, W.A., Sardana, V.V., Long, W.J., Byrnes, V.W. and Emini, E.A. L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents. Chemother. 1995, 39, 2602-2605.
40. Carroll, S.S., Stahlhut, M., Geib, J. and Olsen, D.B. Inhibition of HIV-1 reverse transcriptase by a quinazolinone and comparison with inhibition by pyridinones. J. Biol. Chem. 1994, 269, 32351-32357.
41. Patel, M., McHugh R.J. Jr., Cordova, B.C., Klabe, R.M., Erickson-Viitanen, S., Trainor, G.L. and Rodgers, J.D. Synthesis and evaluation of quinoxalinones as HIV-1 reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett. 2000, 10, 1729-1731.
42. Cocuzza, A.J., Chidester, D.R., Cordova, B.C., Klabe, R.M., Jeffrey, S., Diamond, S., Weigelt, C.A., Ko, S.S., Bacheler, L.T., Erickson-Viitanen, S.K. and Rodgers, J.D. 4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett. 2001, 11, 1389-1392.
43. Rodgers, J.D., Cocuzza, A.J. 2000. DuPont Pharmaceuticals Co, USA. PCT Int. Appl, WO 000 00, 479 (CI. CO7D243/04).
44. Corbett, J.W., Ko, S.S., Rodgers, J.D., Jeffrey, S., Bacheler, L.T., Klabe, R.M., Diamond, S., Lai, C.M., Rabel, S.R., Saye, J.A., Adams, S.P., Trainor, G.L., Anderson, P.S., Erickson- Viitanen, S.K. Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 1999, 43, 2893-2897.
45. Buckheit, R.W. Jr., Hollingshead, M.G., Germany-Decker, J., White, E.L., McMahon, J.B., Allen, L.B., Ross, L.J., Decker, W.D., Westbrook, L., Shannon, W.M., Weislow, O., Bader, J.P. and Boyd, M.R. Thiazolobenzimidazole: biological and biochemical anti-retroviral activity of a new nonnucleoside reverse transcriptase inhibitor. Antiviral Res. 1993, 21, 247-265.
46. Chimirri, A., Grasso, S., Molica, C., Monforte, A.-M., Monforte, P., Zappalà, M., Bruno, G., Nicolò, F., Witvrouw, M., Jonckheere, H., Balzarini, J. and De Clercq, E. Structural features and anti-human immunodeficiency virus (HIV) activity of the isomers of 1-(2′,6′-difluorophenyl -1H,3H-thiazolo[3,4-a]benzimidazole, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Antiviral Chem. Chemother. 1997, 8, 363-370.
47. Maass, G., Immendoerfer, U., Koenig, B., Leser, U., Mueller, B., Goody, R. and Pfaff, E. Viral resistance to the thiazolo-iso-indolinones, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 1993, 37, 2612-2617.
48. Mertens, A., Zilch, H., Konig, B., Schafer, W., Poll, T., Kampe, W., Seidel, H., Leser, U. and Leinert, H. Selective non-nucleoside HIV-1 reverse transcriptase inhibitors. New 2,3-dihydrothiazolo [2,3-a]isoindol-5(9H)-ones and related compounds with anti-HIV-1 activity. J. Med. Chem. 1993, 36, 2526-2535.
49. Nugent, R.A., Schlachter, S.T., Murphy, M.J., Cleek, G.J., Poel, T.J., Wishka, D.G., Graber, D.R., Yagi, Y., Keiser, B.J., Olmsted, R.A., Kopta, L.A., Swaney, S.M., Poppe, S.M., Morris, J., Tarpley, W.G. and Thomas, R.C. Pyrimidine thioethers: a novel class of HIV-1 reverse transcriptase inhibitors with activity against BHAP-resistant HIV. J. Med. Chem. 1998, 41, 3793-3803.
50. Wishka, D.G., Graber, D.R., Kopta, L.A., Olmsted, R.A., Friis, J.M., Hosley, J.D., Adams, W.J., Seest, E.P., Castle, T.M., Dolak, L.A., Keiser, B.J., Yagi, Y., Jeganathan, A., Schlachter, S.T., Murphy, M.J., Cleek, G.J., Nugent, R.A., Poppe, S.M., Swaney, S.M., Han, F., Watt, W., White, W.L., Poel, T.-J., Thomas, R.C., Voorman, R.L., Stefanski, K.J., Stehle, R.G., Tarpley, W.G. and Morris, J. (-)-6-Chloro-2-[(1-furo[2,3-c]pyridin-5-yl-ethyl)thio]-4-pyrimidinamine, PNU-142721, a new broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitor. J. Med. Chem. 1998, 41, 1357-1360.
51. Arranz, E., Díaz, J.A., Ingate, S.T., Witvrouw, M., Pannecouque, C., Balzarini, J., De Clercq, E. and Vega, S. Novel 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives as non-nucleoside reverse transcriptase inhibitors that inhibit the human immunodeficiency virus type 1 (HIV-1) replication. J. Med. Chem. 1998, in press.
52. Witvrouw, M., Arranz, M.E., Pannecouque, C., Declercq, R., Jonckheere, H., Schmit, J.-C., Vandamme, A.M., Diaz, J.A., Ingate, S.T., Desmyter, J., Esnouf, R., Van Meervelt, L., Vega, S., Balzarini, J. and De Clercq, E. 1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immuno-deficiency virus type 1 (HIV-1) reverse transcriptase inhibitors (NNRTIs) with anti-HIV-1 activity. Antimicrob. Agents Chemo-ther. 1998, 42, 618-623.
53. Ijichi, K., Fujiwara, M., Hanasaki, Y., Watanabe, H., Katsuura, K., Takayama, H., Shirakawa, S., Sakai, S.-I., Shigeta, S., Konno, K., Yokota, T. and Baba, M. Potent and specific inhibition of human immunodeficiency virus type 1 replication by 4-(2,6-dichloro-phenyl)1,2,5-thiadiazol-3-Y1 N,N-dialkylcarbamate derivatives. Antimicrob. Agents Chemother. 1995, 39, 2337-2340.
54. Ijichi, K., M. Fujiwara, H. Nagano, Y, Matsumoto, Y. Hanasaki, T. Ide, K. Katsuura, H. Takayama, S. Shirakawa, N. Aimi, S. Shigeta, K. Konno, M. Matsushima, T. Yokota, and M. Baba. Anti-HIV-1 activity of thiadiazole derivatives: a structure-activity relationship, reverse transcriptase inhibition, and lipophilicity. Antiviral Res. 1996,31, 87-94.
55. Fujiwara, M., Ijichi, K., Hanasaki, Y., Ide, T., Katsuura, K., Takayama, H., Aimi, N., Shigeta, S., Konno, K., Yokota, T., Baba, M. Thiadiazole derivatives: highly potent and selective inhibitors of human immunodeficiency virus type 1 (HIV-1) replications in vitro. Microbiol. Immunol. 1997, 41, 301-308.
56. Hanasaki, Y., Watanabe, H., Katsuura, K., Takayama, H., Shirakawa, S. Yamaguchi, K., Sakai, S., Ijichi, K., Fujiwara, M., Konno, K., Yokota, T., Shigeta, S. and Baba, M. Thiadiazole derivatives: highly potent and specific HIV-1 reverse transcriptase inhibitors. J. Med. Chem. 1995, 38, 2038-2040.
57. Fujiwara, M., Kodama, E.N., Okamoto, M., Tokuhisa, K., Teruhiko, I., Hanasaki, Y., Katsuura, K., Takayama, H., Aimi, N., Mitsuya, H., Shigeta, S., Konno, K., Yokota, T. and Baba, M. Characterization of human immunodeficiency virus type 1 strains resistant to the non-nucleoside reverse transcriptase inhibitor RD4-2217. Antiviral Chem. Chemother. 1999, 10, 315-230.
58. McMahon, J.B., Gulakowski, R.J., Weislow, O.S., Schultz, R.J., V.L. Narayanan, D.J. Clanton, R. Pedemonte, F.W. Wassmundt, Buckheit R.W. Jr., Decker, W.D., White, E.L., Bader, J.P. and Boyd, M.R. Diarylsulfones, a new chemical class of nonnucleoside antiviral inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 1993, 37, 754-760.
59. Buckheit, R.W. Jr., Fliakas-Boltz, V., Russel, J.D., Snow, M., Pallansch, L.A., Yang, S.S., Bader, J.P., Khan, T.N. and Zanger, M. A diarylsulphone non-nucleoside reverse transcriptase inhibitor with a unique sensitivity profile to drug-resistant virus isolates. Antiviral Chem. Chemother. 1996, 7, 243-252.
60. Artico, M., Silvestri, R., Massa, S., Loi, A.G., Corrias, S., Piras, G., and La Colla, P. 2-Sulfonyl-4-chloroanilino moiety: a potent pharmacophore for the anti-human immunodeficiency virus type 1 activity of pyrrolyl aryl sulfones. J. Med. Chem. 1996, 39, 522-530.
61. Artico, M., Silvestri, R., Pagnozzi, E., Bruno, B., Novellino, E., Greco, G., Massa, S., Ettorre, A., Loi, A.G., Scintu, F. and La Colla, P. Structure-based design, synthesis, and biological evaluation of novel pyrrolyl aryl sulfones: HIV-1 non-nucleoside reverse transcriptase inhibitors active at nanomolar concentrations. J. Med. Chem. 2000, 43, 1886-1891.
62. Cushman, M., Golebiewski, W.M., Graham, L., Turpin, J.A., Rice, W.G., Fliakas-Boltz, V. and Buckheit R.W. Jr. Synthesis and biological evaluation of certain alkenyldiarylmethanes as anti-HIV-1 agents which act as non-nucleoside reverse transcriptase inhibitors. J. Med. Chem. 1996, 39, 3217-3227.
63. Cushman, M., Casimiro-Garcia, A., Hejchman, E., Ruell, J.A., Huang, M., Schaeffer, C.A., Williamson, K., Rice, W.G. and Buckheit, R.W. Jr. New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors. J. Med. Chem. 1998, 41, 2076-2089.
64. Casimiro-Garcia, A., Micklatcher, M., Turpin, J.A., Stup, T.L., Watson, K., Buckheit, R.W. and Cushman, M. Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors. J. Med. Chem. 1999, 42, 4861-4874.
65. Xu, G., Micklatcher, M., Silvestri, M.A., Hartman, T.L., Burrier, J., Osterling, M.C., Wargo, H., Turpin, J.A., Buckheit R.W. Jr., and Cushman, M. The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors. J. Med. Chem. 2001, 44, 4092-4113.
66. Kashman, Y., Gustafson, K.R., Fuller, R.W., Cardellina J.H. II, McMahon, J.B., Currens, M.J., Buckheit R.W. Jr., Hughes, S.H., Cragg, G.M. and Boyd, M.R. The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum. J. Med. Chem. 1992, 35, 2735-2743.
67. Zembower, D.E., Liao, S., Flavin, M.T., Xu, Z.-Q., Stup, T.L., Buckheit R.W. Jr., Khilevich, A., Mar, A.A. and Sheinkman, A.K. Structural analogues of the calanolide anti-HIV agents. Modification of the trans-10, 11-dimethyldihydropyran-12-ol ring (ring C). J. Med. Chem. 1997, 40, 1005-1017.
68. Flavin, M.T., Rizzo, J.D., Khilevich, A., Kucherenko, A., Sheinkman, A.K., Vilaychack, V., Lin, L., Chen, W., Greenwood, E.M., Pengsuparp, P., Pezzuto, J.M., Hughes, S.H., Flavin, T.M., Cibulski, M., Boulanger, W.A., Shone, R.L. and Xu, Z.-X. Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+/-)-calanolide A and its enantiomers. J. Med. Chem. 1996, 39, 1303-1313.
69. Patil, A.D., Freyer, A.J., Eggleston, D.S., Haltiwanger, R.C., Bean, M.F., Taylor, P.B., Caranfa, M.J., Breen, A.L., Bartus, H.R., Johnson, R.K., Hertzberg, R.P. and Westley, J.W. The inophyllums, novel inhibitors of HIV-1 reverse transcriptase isolated from the Malaysian tree, Calophyllum inophyllum Linn. J. Med. Chem. 1993, 36, 4131-4138.
70. Buckheit, R.W. Jr., White, E.L., Fliakas-Boltz, V., Russell, J., Stup, T.L., Kinjerski, T.L., Osterling, M.C., Weigand, A. and Bader, J.P. Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide. Antimicrob. Agents Chemother. 1999, 43, 1827-1834.
71. Ludovici, D.W., Kavash, R.W., Kukla, M.J., Ho, C.Y., Ye, H., De Corte, B.L., Andries, K., de Bethune, M.P., Azijn, H., Pauwels, R., Moereels, H.E., Heeres, J., Koymans, L.M., de Jonge, M.R., Van Aken, K.J., Daeyaert, F.F., Lewi, P.J., Das, K., Arnold, E. and Janssen, P.A. Evolution of anti-HIV drug candidates. Part 2: Diaryltriazine (DATA) analogues. Bioorg. Med. Chem. Lett. 2001, 11, 2229-2234.
72. Fujiwara, T., Sato, A., El-Farrash, M., Miki, S., Abe, K., Isaka, Y., Kodama, M., Wu, Y., Chen, L.B., Harada, H., Sugimoto, H., Hatanaka, M. and Hinuma, Y. S-1153 inhibits replication of known rug-resistant strains of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 1998, 42, 1340-1345.
73. Williams, T.M., Ciccarone, T.M., MacTough, S.C., Rooney, C.S., Balani, S.K., Condra, J.H., Emini, E.A., Goldman, M.E., Greenlee, W.J., Kauffman, L.R., O'Brien, J.A., Sardana, V.V., Schleif, W.A., Theoharides, A.D. and Anderson, P.S. 5-Chloro-3-(phenylsulfonyl) indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase. J. Med. Chem. 1993, 36, 1291-1294.
74. Buckheit, R.W. Jr., Fliakas-Boltz, V., Decker, W.D., Roberson, J.L., Pyle, C.A., White, E.L., Bowdon, B.J., McMahon, J.B., Boyd, M.R., Bader, J.P., Nickel, D.G., Bart, H. and Antonucci, T.K. Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors. Antiviral Res. 1996, 25, 43-56.
75. Terrett, N.K., Bojanic, D., Merson, J.R. and Stephenson, P.T. Imidazo[2′,3′:6,5 ] dipyrido[3,2- b: 2′,3′-e]-1, 4-diazepines: nonnucleoside HIV-1 reverse transcriptase inhibitors with greater enzyme affinity than nevirapine. Bioorg. Med. Chem. Lett. 1992, 2, 1745-1750.
76. Livermore, D.G.H., Bethell, R.C., Cammack, N., Hancock, A.P., Hann, M.M., Green, D.V.S., Lamont, R.B., Noble, S.A., Orr, D.C., Payne, J.J., Ramsay, M.V.J., Shingler, A.H., Smith, C., Storer, R., Williamson, C. and Willson, T. Synthesis and anti-HIV-1 activity of a series of imidazo[1,5-b]pyridazines. J. Med. Chem. 1993, 36, 3784-3794.
77. Bellarosa, D., Antonelli, G., Bambacioni, F., Giannotti, D., Viti, G., Nannicini, R., Giachetti, A., Dianzani, F., Witvrouw, M., Pauwels, R., Desmyter, J. and De Clercq, E. New arylpyrido-diazepine and -thiodiazepine derivatives are potent and highly selective HIV-1 inhibitors targeted at the reverse transcriptase. Antiviral Res. 1996, 30, 109-124.
78. Althaus, I.W., Chou, K.-C., Lemay, R.J., Franks, K.M., Deibel, M.R., Kezdy, F.J., Resnick, L., Busso, M.E., So, A.G., Downey, K.M., Romero, D.L., Thomas, R.C., Aristoff, P.A., Tarpley, W.G. and Reusser, F. The benzylthiopyrimidine U-31,355, a potent inhibitor of HIV-1 reverse transcriptase. Biochem. Pharmacol. 1996, 51, 743-750.
79. Dollé, V., Nguyen, C.H., Aubertin, A.M., Kirn, A., Andreola, M.L., Jamieson, G., Tarrago-Litvak, L. and Bisagni, E. A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors. J. Med. Chem. 1995, 38, 4679-4686.
80. Jourdan, F., Renault, J., Fossey, C., Bureau, R., Ladurée, D., Robba, M., Aubertin, A.M. and Kirn, A. Design, synthesis and antiviral activity of new pyridinone derivatives. Antiviral Chem. Chemother. 1997, 8, 161-172.
81. Kim, D.-K., Gam, J., Kim, Y.-W., Lim, J., Kim, H.-T. and Kim, K.H. Synthesis and anti-HIV-1 activity of a series of 1-alkoxy-5-alkyl-6-(arylthio)uracils. J. Med. Chem. 1997, 40, 2363-2373.
82. Kelly, T.A., McNeil, D.W., Rose, J.M., David, E., Shih, C.-K. and Grob, P.M. Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 6. 2-Indol-3-yl- and 2-azaindol-3-yl-dipyridodiazepinones. J. Med. Chem. 1997, 40, 2430-2433.
83. Campiani, G., Nacci, V., Fiorini, I., De Filippis, M.P., Garofalo, A., Greco, G., Novellino, E., Altamura, S. and Di Renzo, L. Pyrrolo-benzothiazepinones and pyrrolobenzoxazepinones: novel and specific non-nucleoside HIV-1 reverse transcriptase inhibitors with antiviral activity. J. Med. Chem. 1996, 39, 2672-2680.
84. Antonucci, T., Warmus, J.S., Hodges, J.C. and Nickell, D.G. Characterization of the antiviral activity of highly substituted pyrroles: a novel class of non-nucleoside HIV-1 reverse transcriptase inhibitor. Antiviral Chem. Chemother. 1995, 6, 98-108.
85. Barth, B., Dierich, M., Heinisch, G., Jenny, V., Matuszczak, B., Mereiter, K., Planer, R., Schöpf, I., Stoiber, H., Traugott, T. and Aufschnaiter,P. v.Pyridazino[3,4-b][1,5]benzoxazepin-5(6H)-ones: synthesis and biological evaluation. Antiviral Chem. Chemother. 1996, 7, 300-312.
86. Krikorian, D., Parushev, S., Tarpanov, V., Mechkarova, P., Mikhova, B., Botta, M., Corelli, F., Maga, G. and Spadari, S. Synthesis and biological evaluation of imidazo[1,2-d][1,4] benzodiazepines and related compounds as potential anti-HIV-1 agents. Med. Chem. Res. 1997, 7, 546-556.
87. Silvestri, R., Artico, M., Bruno, B., Massa, S., Novellino, E., Greco, G., Marongiu, M.E., Pani, A,, De Montis, A. and La Colla, P. Synthesis and biological evaluation of 5H-indolo [3,2b][1,5]benzothiazepine derivatives, designed as conformationally constrained analogues of the human immunodeficiency virus type 1 reverse transcriptase inhibitor L-737,126. Antiviral Chem. Chemother. 1998, 9, 139-148.
88. Taylor, D.L., Ahmed, P.S., Chambers, P., Tyms, A.S., Bedard, J., Duchaine, J., Falardeau, G., Lavallée, J.F., Brown, W., Rando, R.F. and Bowlin, T. Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Antiviral Chem. Chemother. 1999, 10, 79-86.
89. D'Aquila, R.T., Hughes, M.D., Johnson, V.A., Fischl, M.A., Sommadossi, J.P., Liou, S.H., Timpone, J., Myers, M., Basgoz, N., Niu, M. and Hirsch, M.S. Nevirapine, zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 1996, 124, 1019-1030.
90. De Lucca, G.V. and Otto, M.J. Synthesis and anti-HIV activity of pyrrolo-[1,2-d]-(1,4)-benzodiazepin-6-ones. Bioorg. Med. Chem. Lett. 1992, 2, 1639-1644.
91. Di Santo, R., Costi, R., Artico, M., Massa, S., Marongiu, M.E., Loi, A.G., De Montis, A. and La Colla, P. 1,2,5-Benzothiadiazepine and pyrrolo[2,1-d][1,2,5]benzo-thiadiazepine derivatives with specific anti-human immunodeficiency virus type 1 activity. Antiviral Chem. Chemother. 1998, 9, 127-137.
92. Campiani, G., Morelli, E., Fabbrini, M., Nacci, V., Greco, G., Novellino, E., Ramunno, A., Maga, G., Spadari, S., Caliendo, G., Bergamini, A., Faggioli, E., Uccella, I., Bolacchi, F., Marini, S., Coletta, M., Nacca, A. and Caccia, S. Pyrrolobenzoxazepinone derivatives as non-nucleoside HIV-1 RT inhibitors: further structure-activity relationship studies and identification of more potent broad-spectrum HIV-1 RT inhibitors with antiviral activity. J. Med. Chem. 1999, 42, 4462-4470.
93. Hara, H., Fujihashi, T., Sakata, T., Kaji, A. and Kaji, H. Tetrahydronaphthalene lignan compounds as potent anti-HIV type 1 agents. AIDS Res. Hum. Retrovir. 1997, 13, 695-705.
94. Wyatt, P.G., Bethell, R.C., Cammack, N., Charon, D., Dodic, N., Dumaitre, B., Evans, D.N., Green, D.V.S., Hopewell, P.L., Humber, D.C., Lamont, R.B., Orr, D.C., Plested, S.J., Ryan, D.M., Sollis, S.L., Storer, R. and Weingarten, G.G. Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase. J. Med. Chem. 1995, 38, 1657-1665.
95. Genin, M.J., Biles, C., Keiser, B.J., Poppe, S.M., Swaney, S.M., Tarpley, W.G., Yagi, Y. and Romero, D.L. Novel 1,5-diphenyl-pyrazole nonnucleoside HIV-1 reverse transcriptase inhibitors with enhanced activity versus the delavirdine-resistant P236L mutant: lead identification and SAR of 3- and 4-substituted derivatives. J. Med. Chem. 2000, 43, 1034-1040.
96. Barreca, M.L., Chimirri, A., De Luca, L., Monforte, A.-M., Monforte, P., Rao, A., Zappala, M., Balzarini, J., De Clercq, E., Pannecouque, C. and Witvrouw, M. Discovery of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV-1 agents. Bioorg. Med. Chem. Lett. 2001, 11, 1793-1796.
97. Corbett, J.W., Pan, S., Markwalder, J.A., Cordova, B.C., Klabe, R.M., Garber, G., Rodgers, J.D. and Erickson-Viitanen, S.K. 3,3a-Dihydropyrano[4,3,2-de]quinazolin-2(1H)-ones are potent nonnucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett. 2001, 11, 211-214.
98. Ludovici, D.W., Kukla, M.J., Grous, P.G., Krishnan, S., Andries, K., de Béthune, M.-J., Azijn, H., Pauwels, R., De Clercq, E., Arnold, E. and Janssen, P.A.J. Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU). Bioorg. Med. Chem. Lett. 2001, 11, 2225-2228.
99. Ludovici, D.W., De Corte, B.L., Kukla, M.J., Ye, H., Ho, C.Y., Lichtenstein, M.A., Kavash, R.W., Andries, K., de Béthune, M.-P., Azijn, H., Pauwels, R., Lewi, P.J., Heeres, J., Koymans, L.M.H., de Jonge, M.R., Van Aken, K.J.A., Daeyaert, F.F.D., Das, K., Arnold, E. and Janssen, P.A.J. Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. Bioorg. Med. Chem. Lett. 2001, 11, 2235-2239.
100. Andries, K., De Béthune, M.-P., Kukla, M.J., Azijn, H., Lewi, P.J., Janssen, P.A.J. and Pauwels, R. 2000. R165335-TMC125, a novel non nucleoside reverse transcriptase inhibitor (NNRTI) with nanomolar activity against NNRTI resistant HIV strains. In Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada.
101. Gazzard, B., Pozniak, A., Arasteh, K., Staszewski, S., Rozenbaum, W., Yeni, P., van't Klooster, G., De Dier, K., Peeters, M., de Béthune, M.P., Graham, N. and Pauwels, R. 2002. TMC125, a next-generation NNRTI, demonstrates high potency after 7 days therapy in treatment-experienced HIV-1-infected individuals with phenotypic NNRTI resistance. In Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, Washington, USA.
102. Sankatsing, S., Weverling, G., van't Klooster, G., Prins, J. and Lange, J. 2002. In Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, Washington, USA.
103. Chan, J.H., Hong, S.J., Hunter R.N. III, Orr, E.G., Cowan, J.R., Sherman, D.B., Sparks, S.M. and Reitter, B.E. 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J. Med. Chem. 2001, 44, 1866-1882.
104. Buckheit, R.W. Jr., Watson, K., Fliakas-Boltz, V., Russell, J., Loftus, T.L., Osterling, M.C., Turpin, J.A., Pallansch, L.A., White, E.L., Lee, J.-W., Lee, S.-H., Oh, J.-W., Kwon, H.-S., Chung, S.-G. and Cho, E.-H. SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2. Antimicrob. Agents Chemother. 2001, 45, 393-400.
105. Balzarini, J., Stevens, M., Andrei, G., Snoeck, R., Strunk, R., Pierce, J.B., Lacadie, J.A., De Clercq, E., Pannecouque, C. Pridine oxide derivatives: structure-activity relationship for inhibition of human immunodeficiency virus and cytomegalovirus replication in cell culture. Helv. Chimica Acta 2002, 85, 2961-2974.
106. Stevens, M., Pannecouque, C., De Clercq, E. and Balzarini, J. Inhibition of human immunodeficiency virus (HIV) by a new class of pyridine oxide derivatives. Antimicrob. Agents Chemother 2003, 47, 2351-2357.
107. Stevens, M., Pannecouque, C., De Clercq, E. and Balzarini, J. Novel human immunodeficiency virus (HIV) inhibitors having a dual mode of anti-HIV action. Antimicrob. Agents Chemother 2003, 47, 3109-3116.
108. Balzarini, J. and De Clercq, E. 1998. Biochemical pharmacology of nucleoside and non-nucleoside analogues active against HIV reverse transcriptase. In: Textbook of AIDS Medicine. Merigan, T.C., J.G. Bartlett, and D.P. Bolognesi (eds.). Second Ed. Williams & Wilkins, Baltimore, MD, pp. 815-847 (1998).
109. Balzarini, J., and E. De Clercq. Analysis of inhibition of retroviral reverse transcriptase. Methods in Enzymology 1996, 275, 472-502.
110. Ren, J.S., Esnouf, R., Garman, E., Somers, D., Ross, C., Kirby, I., Keeling, J., Darby, G., Jones, Y., Stuart, D. and Stammmers, D. High resolution structure of HIV-1 RT: Insights from four RT-inhibitor complexes. Nat. Struct. Biol. 1995, 2, 293-302.
111. Esnouf, R., J. Ren, C. Ross, Y. Jones, D. Stammers, and D. Stuart. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nature Struct. Biol. 1995, 2, 303-308.
112. Kohlstaedt, L.A, Wang, J., Friedman, J.M., Rice, P.A. and Steitz, T. A Crystal structure at 3.5Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992, 256, 1783-1790.
113. Nanni, R.G., Ding, J., Jacobo-Molina, A., Hughes, S.H., and Arnold, E. Review of HIV-1 reverse transcriptase three-dimensional structure: Implications for drug design. Perspect. Drug. Discov. Des. 1993, 1, 129-150.
114. Jacobo-Molina, A., Ding, J., Nanni, R.G., Clarck, A.D., Lu, X., Tantillo, C., Williams, R.L., Kame, G., Ferris, A.L., Clarck, P., Hitzi, A., Hughes, S.H. and Arnold, E. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å shows bent DNA. Proc. Natl. Acad. Sci. 1993, 90, 6320-6324.
115. Balzarini, J. Strategies to suppress resistance to drugs targeted at human immunodeficiency virus reverse transcriptase by combination therapy. Commentary. Biochem. Pharmacol. 1999, 58, 1-27.
116. Vandamme, A.-M., Van Vaerenbergh, K. and De Clercq, E. Anti-human immunodeficiency virus drug combination strategies. Antivir. Chem. Chemother. 1998, 9, 187-203.
117. Patel, P.H., Jacobo-Molina, A., Ding, J., Tantillo, C., Clarck, A.D., Raag R. Jr., Nanni, R.G., Hughes, S.H. and Arnold, E. Insights into DNA polymerization mechanisms from structure and function analysis of HIV-1 reverse transcriptase. Biochemistry 1995, 34, 5351-5363.
118. Balzarini, J., Pérez-Pérez, M.-J., San-Félix, A., Camarasa, M.-J., Bathurst, I.C., P.J. Barr, and De Clercq, E. Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2′,5′-bis-O-(tert-butyldimetlhylsilyl)-β-D- ribofuranosyl]-3′-spiro-5″-(4″-amino-1″-2″ -oxathiole-2″, 2″-di-oxide)thymine (TSAO-T). J. Biol. Chem. 1992, 267, 11831-11838.
119. Debyser, Z., Pauwels, R., Andries, K. and De Clercq, E. Specific HIV-1 reverse transcriptase inhibitors. J. Enzyme Inhibition 1992, 6, 47-53
120. Frank, K.B., Noll, G.J., Connell, E.V. and Sim, I.S. Kinetic interaction of human immunodeficiency virus type 1 reverse transcriptase with the antiviral tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepine-2-(1H)-thione compound, R82150. J. Biol. Chem. 1991, 266, 14232-14236.
121. White, E.L., Buckheit R.W. Jr., Ross, L.J., Germany, J.M., Andries, K., Pauwels, R., Janssen, W P.A.J., Shannon, M. and Chirigos, M.A. A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates. Antiviral Res. 1991, 26, 257-266.
122. Wu, J.C., Warren, T.C., Adams, J., Proudfoot, J., Skiles, J., Raghavan, P., Perry, C., Potocki, I., Farina, P.R. and Grob, P.M. A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site. Biochemistry 1991, 30, 2022-2026.
123. Howard, K.J., Frank, K.B., Sim, I.S. and Le Grice, S.F. Reconstitution and properties of homologous and chimeric HIV-1. HIV-2 p66.p51 reverse transcriptase. J. Biol. Chem. 1991, 266, 23003-23009.
124. Shih, C.K., Rose, J.M., Hansen, G.L., Wu, J.C., Bacolla, A. and Griffin, J.A. Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonucleoside analog inhibitors. Proc. Natl. Acad. Sci. USA 1991, 88, 9878-9882.
125. Yang, G., Song, Q., Charles, M., Drosopoulos, W.C., Arnold, E. and Prasad, V.R. Use of chimeric human immunodeficiency virus types 1 and 2 reverse transcriptases for structure-function analysis and for mapping susceptibility to nonnucleoside inhibitors. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1996, 11, 326-333.
126. Hizi, A., Tal, R., Shaharabany, M., Currens, M.J., Boyd, M.R., Hughes, S.H. and McMahon, J.B. Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors. Antimicrob. Agents Chemother. 1993, 37, 1037-1042.
127. Isaka, Y., Sato, A., Kawauchi, S., Suyama, A., Miki, S., Hayami, M. and Fujiwara, T. Construction of the chimeric reverse transcriptase of simian immunodeficiency virus sensitive to nonnucleoside reverse transcriptase inhibitor. Microbiol. Immunol. 1998, 42, 195-202.
128. Misra, H.S., Pandey, P.K. and Pandey, V.N. An enzymatically active chimeric HIV-1 reverse transcriptase (RT) with the RNase-H domain of murine leukaemia virus RT exists as a monomer. J. Biol. Chem. 1998, 273, 9785-9789.
129. Amacker, M. and Hubscher, U. Chimeric HIV-1 and feline immunodeficiency virus reverse transcriptases: critical role of the p51 subunit in the structural integrity of heterodimeric lentiviral DNA polymerises. J. Mol. Biol. 1998, 278, 757-765.
130. Schinazi, R.F., Larder, B.A. and Mellors, J.N. Mutations in retroviral genes associated with drug resistance: 2000-2001 update. Int. Antivir. News 2000, 8, 65-91.
131. Auwerx, J., North, T.W., Preston, B.D., Klarmann, G.J., De Clercq, E. and Balzarini, J. Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptase: role of the subunits in resistance/senstivity to non-nucleoside reverse transcriptase inhibitors. Mol. Pharmacol. 2002, 61, 400-406.
132. Ren, J., Diprose, J., Warren, J., Esnouf, R.M., Bird, L.E., Ikemizu, S., Slater, M., Milton, J., Balzarini, J., Stuart, D.I. and Stammers, D.K. Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases. J. Biol. Chem. 2000, 275, 5633-5639.
133. Spence, R.A., Kati, W.M., Anderson, K.S. and Johnson, K.A. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995, 267, 988-993.
134. Fletcher, R.S., Arion, D., Borkow, G., Wainberg, M.A., Dmitrienko, G.I. and Parniak, M.A. Synergistic inhibition of HIV-1 reverse transcriptase DNA polymerase activity and virus replication in vitro by combinations of carboxanilide nonnucleoside compounds. Biochemistry 1995, 34, 10106-10112.
135. Fletcher, R.S., Syed, K., Mithani, S., Dmitrienko, G.I. and Parniak, M.A. Carboxanilide derivative non-nucleoside inhibitors of HIV-1 reverse transcriptase interact with different mechanistic forms of the enzyme. Biochemistry 1995, 34, 4346-4353.
136. Smerdon, S.J., Jäger, J., Wang, J., Kohlstaedt, L.A., Chirino, A.J., Friedman, J.M., Rice, P.A. and Steitz, T.A. Structure of the bindng site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl. Sci. USA. 1994, 91, 3911-3915.
137. Huang, H.F., Chopra, R., Verdine, G.L. and Harrison, S.C. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase. Implications of drug resistance. Science 1998, 282, 1669-1675.
138. Stammers, D.K., Somers, D.O., Ross, C.K., Kirby, I., Ray, P.H., Wilson, J.E., Norman, M., Ren, J.S., Esnouf, R.M., Garman, E.F., Jones, E.Y. and Stuart, D.I. Crystals of HIV-1 reverse transcriptase diffracting to 2.2 Å resolution. J. Mol. Biol. 1994, 242, 586-588.
139. Hellmig, B., Woolf, D.J., Debouck, C. and Harrison, S.C. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 1995, 92, 1222-1226.
140. Hsiou,Y., Das, K., Ding, J., Clarck A.D. Jr., Boyer, P.L., Janssen, P.A.J., Kleim, J.-P., Rosner, M., Hughes, S.H. and Arnold, E. 1998. Crystal structures of wild-type and mutant HIV-1 reverse transcriptase and non-nucleoside inhibitors: Implications for drug resistance mechanisms. In Abstracts of the Second International Workshop on HIV Drug Resistance and Treatment Strategies. Italy.
141. Hsiou, Y., Ding, J., Das, K., Clark A.D. Jr., Boyer, P.L., Lewi, P., Janssen, P.A., Kleim, J.P., Rosner, M., Hughes, S.H. and Arnold, E. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. J. Mol. Biol. 2001, 309, 437-445.
142. Ren, J., Nichols, C., Bird, L., Chamberlain, P., Weaver, K., Short, S., Stuart, D.I. and Stammers, D.K. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation nonnucleoside inhibitors. J. Mol. Biol. 2001, 312, 795-805.
143. Chamberlain, P.P., Ren, J., Nichols, C.E., Douglas, L., Lennerstrand, J., Larder, B.A., Stuart, D.I. and Stammers, D.K. Crystal structures of zidovudine- or lamivudine-resistant human immunodeficiency virus type 1 reverse transcriptases containing mutations at codons 41, 184 and 215. J. Virol. 2002, 76, 10015-10019.
144. Esnouf, R.M., Ren, J., Garman, E.F., 'ON Somers, D., Ross, C.K., Jones, E.Y., Stammers, D.K. and Stuart, D.I. Continuous and discontinuous changes in the unit cell of HIV-1 reverse transcriptase crystals on dehydration. Acta Cryst. 1998, D54, 938-953.
145. Esnouf, R.M., Ren, J., Hopkins, A.L., Ross, A.K., Jones, E.Y., Stammers, D.K. and Stuart, D.I. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Proc. Natl. Acad. Sci. 1997, 94, 3984-3989.
146. Miyasaka, C., Walker, R.T., Tanaka, H., Stammers, D.K. and Stuart, D.I. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J. Med. Chem. 1996, 39, 1589-1600.
147. Rodríguez- Barrios, F., Pérez, C., Lobatón, E., Velázquez, S., Chamorro, C., San-Félix, A., Pé rez-Pérez, M.-J., Camarasa, M.-J., Pelemans, H., Balzarini, J. and Gago, F. Identification of a putative binding site for [2′,5′-bis-O-(tert-butyldimethylsilyl)-β-D- ribofuranosyl]-3′-spiro-5″-(4″-amino-1″,2″ -oxathiole-2″, 2″-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase. J. Med. Chem. 2001, 44, 1853-1865.
148. Arion, D., Fletcher, R.S., Borkow, G., Camarasa, M.J., Balzarini, J., Dmitrienko, G.I. and Parniak, M.A. Differences in the inhibition of human immunodeficiency virus type 1 reverse trans-criptase DNA polymerase activity by analogs of nevirapine and [2′,5′-bis-O-(tert-butyldimethylsilyl)-3′ -spiro-5″-(4″-amino-1″, 2″-oxathiole-2″ ,2″-dioxide] (TSAO). Mol. Pharmacol. 1996, 50, 1057-1064.
149. Sluis-Cremer, N., Dmitrienko, G.I., Balzarini, J., Camarasa, M. and Parniak, P.A. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[spiro-[4″-amino-2″,2″-dioxo-1″,2″ -oxathiole-5″,3′-[2′, 5′ -bis-O-(tert-butyldimethylsilyl) -β -D-ribofuranosyl]]]-3-ethylthymine. Biochemistry 2000, 39, 1427-1433.
150. Harris, D., Lee, R., Misra, H.S., Pandey, P.K. and Pandey, V.N. The p51 subunit of human immunodeficiency virus type 1 reverse transcriptase is essential in loading the p66 subunit on the template primer. Biochemistry 1998, 37, 5903-5908.
151. Restle, T., Müller, B. and Goody, R.S. Dimerization of human immunodeficiency virus type 1 reverse transcriptase. J. Biol. Chem. 1990, 265, 8986-8988.
152. Divita, G., Restle, T., Goody, R.S., Chermann, J.-C. and Baillon, J.G. Inhibition of human immunodeficiency virus type 1 reverse transcriptase dimerization using synthetic peptides derived from the connection domain. J. Biol. Chem. 1994, 269, 13080-13083.
153. Divita, G., Baillon, J.G., Rittinger, K., Chermann, J.-C. and Goody, R.S. Interface peptides as structure-based human immunodeficiency virus reverse transcriptase inhibitors. J. Biol. Chem. 1995, 270, 28642-28646.
154. Morris, M.C., Robert-Hebmann, V., Chaloin, L., Mery, J., Heitz, F., Devaux, C., Goody, R.S. and Divita, G. A new potent HIV-1 reverse transcriptase inhibitor. J. Biol. Chem. 1999, 274, 24941-24946.
155. Ren, J., Bird, L.E., Chamberlain, P.P., Stewart-Jones, G.B., Stuart, D.I. and Stammers, D.K. Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA 2002, 99, 14410-14415.
156. Balzarini, J., Karlsson, A., Sardana, V.V., Emini, E.A., Camarasa, M.-J. and De Clercq, E. Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C → C181I)RT HIV-1 mutants. Proc. Natl. Acad. Sci. USA 1994, 91, 6599-6603.
157. Ding, J., Das, K., Moereels, H., Koymans, L., Andries, K., Janssen, P.A.J., Hughes, S.H. and Arnold, E. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat. Struct. Biol. 1995, 2, 407-415.
158. Boyer, P.L., Ding, J., Arnold, E. and Hughes, S.H. Subunit specificity of mutations that confer resistance to non-nucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 1994, 38, 1909-1914.
159. 138 → Lys on the p51 subunit. J. Biol. Chem. 1994, 269, 25255-25258.
160. Balzarini J., Karlsson, A., Pérez-Pérez, M.-J., Vrang, L., Walbers, J., Zhang, H., Oberg, B., Vandamme, A.-M. and De Clercq, E. HIV-1 specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase. Virology 1993, 192, 246-253.
161. Balzarini, J., Karlsson, A., Vandamme, A.-M., Pérez-Pérez, M.-J., Zhang, H., Vrang, L., Öberg, B., Bäckbro, K., Unge, T., San-Félix, A., Velazquez, S., Camarasa, M.-J. and De Clercq, E. Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2′,5′-bis-O-(tert-butyldimethylsilyl)-3′ -spiro-5″-(4″-amino-1″, 2″-oxathiole-2″ ,2″-dioxide)]-β-D-pentofuranosyl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors Proc. Natl. Acad. Sci. USA 1993, 90, 6952-6956.
162. Balzarini, J., Kleim, J.-P., Riess, G., Camarasa, M.-J., De Clercq, E. and Karlsson, A. Sensitivity of (138 Glu_Lys) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibitors. Biochem. Biophys. Res. Commun. 1994, 201, 1305-1312.
163. Esnouf, R.M., Stuart, D.I., De Clercq, E., Schwartz, E. and Balzarini, J. Models which explain the inhibition of reverse transcriptase by HIV-1-specific (thio)carboxanilide derivatives. Biochem. Biophys. Res. Commun. 1997, 234, 458-464.
164. Ren, J., Esnouf, R.M., Hopkins, A.L., Warren, J., Balzarini, J., Stuart, D.I. and Stammers, D. Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives. Biochemistry 1998, 37, 14394-14403.
165. Mellors, J.W., Larder, B.A. and Schinazi, R.F. 1998. Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. Int. Antiviral News, MediTech Media Ltd.
166. Byrnes, V.W., Sardana, V.V., Schleif, W.A., Condra, J.H., Waterbury, J.A., Wolfgang, J.A., Long, W.J., Schneider, C.L., Schlabach, A.J., Wolanski, B.S., Graham, D.J., Gotlib, L., Rhodes, A., Titus, D.L., Roth, E., Blahy, O.M., Quintero, J.C., Staszewski, S. and Emini, E.A. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors. Antimicrob. Agents Chemother. 1993, 37, 1576-1579.
167. Richman, D.D. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob. Agents Chemother. 1993, 37, 1207-1213.
168. Balzarini, J. Karlsson, A., Pérez-Pérez, M.-J., Camarasa, M.-J., Tarpley, W.G., and De Clercq, E. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells by combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. J. Virol. 1993, 67, 5353-5359.
169. Richman, D.D., Havlir, D., Corbeil, J., Looney, D., Ignacio, C., Spector, S.A., Sullivan, J., Cheeseman, S., Barringer, K., Pauletti, D., Myers, C.-K., and Griffin, J. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 1994, 68, 1660-1666.
170. Vasudevachari, M.B., Battista, C., Lane, H.C., Psallidopoulos, M.C., Zhao, B., Cook, J., Palmer, J.R., Romero, D.L., Tarpley, W.G. and Salzman, N.P. Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors. Virology 1992, 190, 269-277.
171. Winslow, D.L., Garber, S., Reid, C., Scarnati, H., Korant, B., Emini, E. and Anton, E.D. 1995. Development of high-level resistance to DMP 266 requires multiple mutations in the reverse transcriptase gene. In Abstracts of the Fourth International Workshop on HIV Drug Resistance, 6-9 July 1995, Sardinia, Italy, no. 13.
172. Winslow, D.L., Reid, C., Garber, S., Scarnati, H., Rayner, M. and Anton, E. 1996. Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266. In Abstracts of the Fifth International Workshop on HIV Drug Resistance, 7-12 July 1996, Whistler, Canada, no. 10.
173. Bacheler, L., Weislow, O., Snyder, S. and Hanna, P.G. 1998. Virological Resistance to Efavirenz. Abstracts of the 12th World AIDS Conference, Geneva, Switzerland, no. 41213.
174. Balzarini, J., Brouwer, W.G., Felauer, E.E., De Clercq, E. and Karlsson, A. Activity of various thiocarboxanilide derivatives against wild-type and several mutant human immunodeficiency virus type 1 strains. Antiviral Res. 1995, 27, 219-236.
175. Fan, N., K.B. Rank, D.B. Evans, R.C. Thomas, W.G. Tarpley, and S.K. Sharma.. Simultaneous mutations at Tyr-181 and Tyr-188 in HIV-1 reverse transcriptase prevents inhibition of RNA-dependent DNA polymerase activity by the bisheteroarylpiperazine (BHAP) U-90152s. FEBS Lett. 1995, 370, 59-62.
176. Bacheler, L.T., Anton, E., Jeffrey, S., George, H., Hollis, G., Abremski, A. and Sustiva Resistance Study Team. 1998. RT gene mutations associated with resistance to efavirenz. In Abstracts of the Second International Workshop on HIV Drug Resistance.
177. Olmsted, R.A., Slade, D.E., Kopta, L.A., Poppe, S.M., Poel, T.J., Newport, S.W., Rank, K.B., Biles, C., Morge, R.A., Dueweke, T.J., Yagi, Y., Romero, D.L., Thomas, R.C., Sharma, S.K. and Tarpley, W.G. (Alkylamino)piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIV-1IIIB with reduced replication phenotypes. J. Virol. 1996, 70, 3698-3705.
178. Dueweke, T.J. Pushkarskaya, T., Poppe, S.M., Swaney, S.M., Zhao, Q., Chen, S.Y., Stevenson, M. and Tarpley, W.G. A mutation in revese transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc. Natl. Acad. Sci. 1993, 90, 4713-4717.
179. Kleim, J.P., Winkler, I., Rosner, M., Kirsch, R., Rubsamen-Waigmann, H., Paessens, A. and Reiss, G. In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure on the nonnucleoside reverse transcriptase inhibitor HBY 097. Virology 1997, 231, 112-118.
180. Pelemans, H., Esnouf, R.M., Jonckheere, H., De Clercq, E. and Balzarini, J. Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase. J. Biol. Chem. 1998, 273, 34234-34239.
181. Boyer, P.L., Gao, H.-Q. and Hughes, S.H. A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer. Antimicrob. Agents Chemother. 1998, 42, 447-452.
182. Kleim, J.P., Rosner, M., Winkler, I., Paessens, A., Kirsch, R., Hsiou, Y., Arnold, E. and Riess, G. Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-Val or Ile and Val-75-Leu or Ile) HIV-1 mutants. Proc. Natl. Acad. Sci. USA 1996, 93, 34-38.
183. Larder, B.A. 3-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 1992, 36, 2664-2669.
184. Byrnes, V.W., Emini, E.A., Schleif, W.A., Condra, J.H., Schneider, C.L., Long, W.J., Wolfgang, J.A., Graham, D.J., Gotlib, L., Schlabach, A.J., Wolanski, B.S., Blahy, O.M., Quintero, J.C., Rhodes, A., Roth, E., Titus, D.L. and Sardana, V.V. Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors. Antimicrob. Agents Chemother. 1994, 38, 1404-1407.
185. Mellors, J., Bazmi, H., Schinazi, R.F., Roy, B.M., Hsiou, Y., Arnold, E., Weir, J. and Mayers, D. Novel mutations in the reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. Antimicrob. Agents Chemother. 1995, 39, 1087-1092.
186. Tachedjian, G., Mellors, J., Bazmi, H., Birch, C. and Mills, J. Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet. J. Virol. 1996, 70, 7171-7181.
187. Balzarini, J. and De Clercq, E. Rapid alternation of drug therapy is highly efficient in suppressing the emergence of mutant drug-resistant HIV strains in cell culture. AIDS Res. Hum. Retrovir. 2001, 17, 1625-1634.
188. Anderson, J.N. 2003. A conserved drug target in the HIV genome. Gene. Ther. Mol. Biol., in press.
189. Bronson, E.C. and Anderson, J.N. Nucleotide composition as a driving force in the evolution of retroviruses. J. Mol. Evol. 1994, 38, 506-532.
190. Burns, D.P.W. and Temin, H.M. High rates of frameshift mutations within homo-oligomeric runs during a single cycle of retroviral replication. J. Virol. 1994, 68, 4196-4203.
191. Fitzgerald, D.J., Bronson, E.C. and Anderson, J.N. Compositional similarities between the human immunodeficiency virus and surface antigens of pathogens. AIDS Res. Hum. Retrovir. 1995, 12, 99-109.
192. Meyers, G. Tenth anniversary perspectives on AIDS, HIV: between past and future. AIDS Res. Hum. Retrovir. 1994, 10, 1317-1324.
193. Meyerhans, A., Vartanian, J.-P., Hultgren, C., Plikat, U., Karlsson, A., Wang, L., Eriksson, S. and Wain-Hobson, S. Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools. J. Virol. 1994, 68, 535-540.
194. Martinez, M.A., Vartanian, J.-P. and Wain-Hobson, S. Hypermutagenesis of RNA using human immunodeficiency virus type 1 reverse transcriptase and biased dNTP concentrations. Proc. Natl. Acad. Sci. USA 1994, 91, 11787-11791.
195. Vartanian, J.-P., Meyerhans, A., Åsjö, B. and Wain-Hobson, S. Selection, recombination, and G→A hypermutation of human immunodeficiency virus type 1 genomes. J. Virol. 1991, 65, 1779-1788.
196. Vartanian, J.-P., Meyerhans, A., Sala, M. and Wain-Hobson, S. G→A hypermutation of the human immunodeficiency virus type 1 genome: evidence for dCTP pool imbalance during reverse transcription. Proc. Natl. Acad. Sci. USA 1994, 91, 3092-3096.
197. Coffin, J.M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995, 267, 483-489.
198. Vartanian, J.-P., Sala, M., Henry, M., Wain-Hobson, S. and Meyerhans, A. Manganese cations increase the mutation rate of human immunodeficiency virus type 1 ex vivo. J. Gen. Virol. 1999, 80, 1983-1986.
199. Preston, B.D. and Dougherty, J.P. Mechanisms of retroviral mutation. Trends Microbiol. 1996, 4, 16-21.
200. Balzarini, J., Camarasa, M.-J., Pérez-Pérez, M.-J., San-Félix, A., Velázquez, S., Perno, C.-F., De Clercq, E., Anderson, J.N. and Karlsson, A. Exploitation of the low fidelity of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and the nucleotide composition bias in the HIV-1 genome to alter the drug resistance development of HIV. J. Virol. 2001, 75, 5772-5777.
201. Nelson, T.R. and Davis, J.M. 2002. HIV and AIDS therapeutics: an overview. RBC Capital Markets.1-26.
202. Joly V. on behalf of the M/3331:013B Study Group. 1998. Tolerance and efficacy of delavirdine mesylate (DLV) and zidovudine (ZDV) therapy in the treatment of HIV infected patients (study M/3331/013B). In Abstracts of the 4th International Congress on Drug Therapy in HIV Infection, United Kingdom.
203. Joly, V. and Yeni, P. Non nucleoside reverse transcriptase inhibitors. AIDS Rev. 1999, 1, 37-44.
204. Havlir, D., Cheeseman, S.H., McLaughin, M., Murphy, R., Erice, A., Spector, S.A., Greenough, T.C., Sullivan, J.L., Hall, D. and Myers, M. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J. Infect. Dis. 1995, 171, 537-545.
205. Kagan, S., Jemsek, J., Martin, D.G., Pierone, G., Manion, D.J., Lee, S.R., Ruiz, N. and the DMP 266-24 Clinical Study Team. 1998. Initial effectiveness and tolerability of nelfinavir (NFV) in combination with efavirenz (EFV, Sustiva, DMP 266) in antiretroviral therapy naï ve or nucleoside analogue experience HIV-1 infected patients: characterization in a phase II, open-label, multi-center study at > 36 weeks. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, abstract I-102.
206. Kohlbrenner, V., Dransfield, K., Cotton, D., Robinson, P. and Myers, M. 1996. Cutaneous eruptions associated with nevirapine therapy in HIV-A infected individuals. In Abstracts of the XI International Conference on AIDS, Vancouver, no, Mo.B. 1202.
207. Mayers, D., Jemesk, J., Eyster, E., Tashima, K. and Thompson, M. 1998. A double-blind, placebo-controlled study to assess the safety, tolerability and antiretroviral activity of efavirenz in combination with open-label zidovudine and lamivudine in HIV-1 infected patients (DMP-266-004). 12th World AIDS Conference, Geneva, June 28-July 3, 1998, abstract 22340.
208. Morales-Ramirez, J., Tashima, K., Hardy, D., Johnson, P., Nelson, M., Staszewski, S., Farina, D., Ruiz, N. and the DMP 2666-6 Clinical Study Team. 1998. A phase II, multicenter, randomized, open-label study to compare the antiretroviral activity and tolerability of efavirenz (EFV) + indinavir (IDV), versus EFV + zidovudine (ZDV) + lamivudine (3TC), versus IDV + ZDV + 3TC at 36 weeks (DMP 266-006). 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, USA, abstract I-103.
209. Warren, K.J., Boxwell, D.E., Kim, N.Y. and Drolet, B.A. Nevirapine-associated Stevens-Johnson syndrome. Lancet 1998, 351, 567.
210. Cheeseman, S., Havlir, D., McLaughlin, M.M., Greenough, T.C., Sullivan, J.L., Hall, D., Hattox, S.E., Spector, S.A., Stein, D.S., Myers, M. and Richman, D.D. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1995, 8, 141-151.
211. De Jong, M., S. Vella, A. Carr, et al.. High-dose nevirapine in previously untreated human immunodeficiency virus type-1-infected persons does not result in sustained suppression ofviral replication. J. Infect Dis. 1997, 175, 966-970.
212. Davey, R.T Jr., Chaitt, D.G., Reed, G.F., Freimuth, W.W., Herpin, B.R., Metcalf, J.A., Eastman, P.S., Falloon, J., Kovacs, J.A., Polis, M.A., Walker, R.E., Masur, H., Boyle, J., Coleman, S., Cox, S.R., Wathen, L., Daenzer, C.L. and Lane, H.C. Randomized, controlled phase I/II trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients. Antimicrob. Agents Chemother 1996, 40, 1657-1664.
213. Luzuriaga, K., Bryson, Y., Krogstad, P., Robinson, J., Stechenberg, B., Lamson, M., Cort, S. and Sullivan, J.L. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. New Engl. J. Med. 1997, 336, 1343-1349.
214. Montaner, J., Reiss, P., Cooper, D., Vella, S., Harris, M., Conway, B., Wainberg, M.A., Smith, D., Robinson, P., Hall, D., Myers, M. and Lange, J.M. A randomized, double-blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-infected patients. The INCAS trial. JAMA 1998, 279, 930-937.151.
215. Sargent, S., Green, S., Para, M., Freimuth, W., Wahren, L., Getchel, L. and Greenwald, C. 1998. Sustained plasma viral burden reductions and CD4 increases in HIV-1-infected patients with rescriptor plus retrovir plus epivir. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, USA, abstract no. 699.
216. Bellman, P. Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed. AIDS 1998, 12, 1333-1340.
217. Richman, D., Shih, C.-K., Lowy, I., Rose, J., Prodanovich, P., Goff, S. and Griffin, J. Human immunodeficiency virus type 1 mutants resistant t o nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci. 1991, 88, 11241-11245.
218. Staszewski, S., Massari, F.E., Kober, A., Gohler, R., Durr, S., Anderson, K.W., Schneider, C.L., Waterbury, J.A., Bakshi, K.K., Taylor, V.I., Hildebrand, C.S., Kreisl, C., Hoffstedt, B., Schleif, W.A., von Briesen, H., Rübsamen-Waigmann, H., Calandra, G.B., Ryan, J.L., Stille, W., Emini, E.A., and Byrnes, V.W. Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high level resistance to L-697,661, a non-nucleoside reverse transcriptase inhibitor. J. Infect. Dis. 1995, 171, 159-165.
219. Demeter, L., Shafer, R., Para, M. et al. 1996. Delavirdine (DLV) susceptibility of HIV-1 isolates obtained from patients receiving DLV monotherapy. In Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections. USA.
220. Kemp, S., Bloor, S. Van Cauwenberghe, A., De Koning, I., Van den Eynde, C., Larder, B. and Hertogs, K. 1999. Analysis of 5000 HIV-1 clinical samples reveals complex non-nucleoside RT inhibitor resistance patterns. Resistance Workshop, San Diego, California, USA, 23-26 June 1999. Antiviral Therapy, 4, suppl. 1, p. 20, no. 26.
221. Carr, A., Samaras, K., Burton, S., Freund, J., Chisholm, D.J. and Cooper, D.A. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance due to HIV protease inhibitors. In Abstracts of the 5th Conference on Retroviruses an Opportunistic Infections, Chicago, Illinois, USA, 1998, no. 410.
222. Borkow, G, Barnard, J., Nguyen, T.M., Belmonte, A., Wainberg, M.A., and Parniak, M.A. Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC-781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. J. Virol. 1997, 71, 3023-3030.
223. Barnard, J., Borkow, G. and Parniak, M.A. The thiocarboxanilide nonnucleoside UC-781 is a tight-binding inhibitor of HIV-1 reverse transcriptase. Biochemistry 1997, 36, 7786-7792.
224. Balzarini, J., Naesens, L., Verbeken, E., Laga, M., Van Damme, L., Parniak, M., Van Mellaert, L., Anné, J. and De Clercq, E. Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. AIDS 1998, 12, 1129-1138.